Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 2, 2015, Pages 357-364

  Cangelosi, Michael J ^a   Ortendahl, Jesse D ^b   Meckley, Lisa M ^a,c   Bentley, Tanya G K ^b   Anene, Ayanna M ^b   Shriner, Kelly M ^a   Fox, John ^d  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^c Trinity Partners LLC   (United States)

^d Priority Health   (United States)

Author keywords

asthma; bronchial thermoplasty; bronchoscopy; cost effectiveness; respiratory disease

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR AFFECTING AGENT;

ADD ON THERAPY; ARTICLE; BRONCHIAL THERMOPLASTY; BRONCHIAL THERMOPLASTY DEVICE; BRONCHOSCOPY; BRONCHUS MUSCLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DATA ANALYSIS; DISEASE EXACERBATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; MORTALITY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PROBABILITY; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY ANALYSIS; SEVERE PERSISTENT ASTHMA; STATISTICAL MODEL; ASTHMA; CATHETER ABLATION; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PATHOPHYSIOLOGY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; SEVERITY OF ILLNESS INDEX;

ASTHMA; BRONCHOSCOPY; CATHETER ABLATION; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 84924555342     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.978292     Document Type: Article

References (29)

1. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: united states, 2001-2010. National center for health statistics Vital Health Stat 2012; 3(35):1-67
2. Heaney LG, Horne R. Non-Adherence in difficult asthma: time to take it seriously. Thorax 2012;67:268-70
3. Cochrane GM, Horne R, Chavez P. Compliance in asthma. Resp. Med 1999; 93(11):763-9
4. Mitzner W. Airway Smooth Muscle: the Appendix of the Lung. Am J Respir Crit Care Med 2004;169:787-90
5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: updated 2007. Bethesda, MD: National Institutes of Health; 2007
6. Solway J, Irvin CG. Airway Smooth Muscle as a Target for Asthma Therapy. N Engl J Med 2007;356:1367-9
7. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma: Full Report 2007. National Heart, Lung, and Blood Institute. 2007
8. Danek C, Lombard C, Dungworth D, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol 2004;97: 1946-53
9. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181(2): 116-24
10. Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176(12): 1185-91
11. Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial Thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132(6):1295-302
12. Thomson NC, Rubin AS, Niven RM, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulmonary Med 2011;8
13. Pavord ID, Thomson NC, Niven RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2013;111(5): 402-7
14. Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006;173(9):965-9
15. Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006;28(6):1145-55
16. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;1:32-9
17. Chipps BE, Zeiger RS, Dorenbaum A, et al. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep 2012;1(4): 259-69
18. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126(5):926-38
19. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65(9):1141-8
20. Sullivan SD, Eisner MD, Campbell JD, Omachi TA. Risk of mortality associated with asthma exacerbation. Am J Respir Crit Care Med 2009;179:A4770
21. Centers for disease control and prevention, national center for health statistics. compressed mortality file 1999-2007. CDC WONDER On-line Database, compiled from Compressed Mortality File 1999-2007 Series 20 No. 2M, 2010. Available from: http://wonder.cdc.gov/cmficd10. html [Last accessed on 24 Mar 2011]
22. Danielson E. Health research data for the real world: the MarketScan databases. research and pharmaceutical division, Thompson Medstat. Jan. 2014. Available from: http://truvenhealth.com/Portals/0/Users/031/31/31/PH-13434%200314-MarketScan-WP-web.pdf [Last accessed on 01 June 2014]
23. Red Book 2009: Pharmacs fundamental reference (Red book drug topics). Montvale, NJ: Physicians Desk Reference, Inc; 2009. US Bureau of Labor Statistics
24. Chained consumer price index urban us medical care. 2014 Data File. Available from: http://data.bls.gov/cgi-bin/surveymost?su [Last accessed on 01 Jun 2014]
25. Yang Y, Brazier JE, Tsuchiya A, Young TA. Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Med Decis Making 2011. 31(2):281-91
26. Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: Converting AQLQ into EQ5D indices. 2002;No. 02/1. Located at: Sheffield Health Economics Group: Health Economics and Decision Science Discussion Paper Series, Sheffield
27. Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50, 000 per quality-Adjusted life-year decision rule?. Med Care 2008;46(4):349-56
28. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108(1):39-46
29. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50, 000-per-QALY Threshold. N Engl J Med 2014;371:796-7